Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study.
Ishikawa E, Yokoyama Y, Chishima H, Kasai H, Kuniyoshi O, Kimura M, Hakamata J, Nakada H, Suehiro N, Nakaya N, Nakajima H, Ikemura S, Kawada I, Yasuda H, Terai H, Jibiki A, Kawazoe H, Soejima K, Muramatsu H, Suzuki S, Nakamura T. Ishikawa E, et al. Among authors: kawada i. Invest New Drugs. 2023 Feb;41(1):122-133. doi: 10.1007/s10637-023-01328-9. Epub 2023 Jan 13. Invest New Drugs. 2023. PMID: 36637703 Free PMC article.
A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.
Soejima K, Naoki K, Ishioka K, Nakamura M, Nakatani M, Kawada I, Watanabe H, Nakachi I, Yasuda H, Satomi R, Nakayama S, Yoda S, Ikemura S, Terai H, Sato T, Ohgino K, Arai D, Tani T, Kuroda A, Nishino M, Betsuyaku T. Soejima K, et al. Among authors: kawada i. Cancer Chemother Pharmacol. 2015 Mar;75(3):513-9. doi: 10.1007/s00280-014-2673-8. Epub 2015 Jan 7. Cancer Chemother Pharmacol. 2015. PMID: 25563719 Clinical Trial.
A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer.
Ikemura S, Naoki K, Yasuda H, Kawada I, Yoda S, Terai H, Sato T, Ishioka K, Arai D, Ohgino K, Kamata H, Miyata J, Kabata H, Betsuyaku T, Soejima K. Ikemura S, et al. Among authors: kawada i. Jpn J Clin Oncol. 2015 Apr;45(4):356-61. doi: 10.1093/jjco/hyu226. Epub 2015 Jan 22. Jpn J Clin Oncol. 2015. PMID: 25612761 Clinical Trial.
In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.
Hirano T, Yasuda H, Tani T, Hamamoto J, Oashi A, Ishioka K, Arai D, Nukaga S, Miyawaki M, Kawada I, Naoki K, Costa DB, Kobayashi SS, Betsuyaku T, Soejima K. Hirano T, et al. Among authors: kawada i. Oncotarget. 2015 Nov 17;6(36):38789-803. doi: 10.18632/oncotarget.5887. Oncotarget. 2015. PMID: 26515464 Free PMC article.
Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001).
Miyawaki M, Naoki K, Yoda S, Nakayama S, Satomi R, Sato T, Ikemura S, Ohgino K, Ishioka K, Arai D, Namkoong H, Otsuka K, Miyazaki M, Tani T, Kuroda A, Nishino M, Yasuda H, Kawada I, Koh H, Nakamura M, Terashima T, Sakamaki F, Sayama K, Betsuyaku T, Soejima K. Miyawaki M, et al. Among authors: kawada i. Mol Clin Oncol. 2017 Mar;6(3):409-414. doi: 10.3892/mco.2017.1154. Epub 2017 Feb 6. Mol Clin Oncol. 2017. PMID: 28451422 Free PMC article.
88 results